CompletedInterventionalNot ApplicableUpdated May 7, 2019
The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles | NCT00316641 | Trialant
Unknown statusInterventionalPhase 3Updated Nov 7, 2006
The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients' Lipid Profiles
ClinicalTrials.gov ID
NCT00316641
Lead Sponsor
China Medical University HospitalOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Nov 7, 2006Estimated
Brief Summary
The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients
Hyperlipidemia
Lipid-lowing Tea
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Patient aged 20-65 years;either sex
Patient diagnosed with hyperlipidemia(fasting levels of TC>=200mg/dL),or TG>=200mg/dL but <400mg/dL,or LDL-C>=130mg/dL)
Patient who has signed the informed consent form
Exclusion Criteria:
Patient with pregnancy (or child bearing potential),or in lactation
Patient with any lipid regulating agents within 4 weeks prior to study period
Patient currently taking concomitant medications, such as oral contraceptives, or any medical treatment capable of interfering with lipid metabolism(eg thiazides, β-blockers, cyclosporins, itraconazole erythromycin,and danazol)
Patient with medical history of hypothyroidism, pancreatitis, cholestasis, nephrotic syndrome, gall bladder disease, primary biliary cirrhosis.
Patient with liver dysfunction (SGOT or SGPT>2x ULN)
Patient with renal insufficiency (serum creatinine>1.3mg/dL)
Patient with myocardial infarction,cerebrovascular disease,or major operations within 6 months prior to the study period.